In vitro activity of ciprofloxacin compared with other agents against recent hospital isolates.
Ciprofloxacin's in vitro activity was tested against 385 hospital isolates originating from three geographically distinct regions. Of all strains tested, only three (1 Acinetobacter sp. and 2 Pseudomonas aeruginosa) were ciprofloxacin resistant. Ciprofloxacin was more active against Escherichia coli, Enterobacter cloacae, Enterobacter aerogenes, Acinetobacter sp., Proteus sp., Shigella sp. than gentamicin, mezlocillin and cefotaxime. It was more active than azlocillin and cefsulodin against P. aeruginosa. It was more active than cloxacillin and cefamandole against staphylococci. It was as active as cefotaxime against Klebsiella pneumoniae, Citrobacter freundii and Serratia marcescens. Ciprofloxacin demonstrated similar activity in broth and solid agar. The minimal inhibitory concentrations (MIC's) of all strains were similar to the minimal bactericidal concentrations (MBC's). Ciprofloxacin's MIC was not influenced by increase of the inoculum or addition of human serum and only slightly influenced by anaerobic conditions. Decrease of the medium pH increased the MIC substantially. Ciprofloxacin exhibited a rapid bactericidal effect and had only a minimal post-antibiotic effect. These favorable in vitro characteristics of ciprofloxacin warrant further studies.
D000150:Acinetobacter / Q000187:drug effects; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000892:Anti-Infective Agents, Urinary / Q000494:pharmacology*; D001390:Azlocillin / Q000494:pharmacology; D001419:Bacteria / Q000187:drug effects*; D002435:Cefamandole / Q000494:pharmacology; D002439:Cefotaxime / Q000494:pharmacology; D002441:Cefsulodin / Q000494:pharmacology; D002939:Ciprofloxacin; D002954:Citrobacter / Q000187:drug effects; D003023:Cloxacillin / Q000494:pharmacology; D004754:Enterobacter / Q000187:drug effects; D004926:Escherichia coli / Q000187:drug effects; D005839:Gentamicins / Q000494:pharmacology; D006801:Humans; D007711:Klebsiella pneumoniae / Q000187:drug effects; D008802:Mezlocillin / Q000494:pharmacology; D010403:Penicillin Resistance; D011511:Proteus / Q000187:drug effects; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D011804:Quinolines / Q000494:pharmacology*; D012706:Serratia marcescens / Q000187:drug effects; D012760:Shigella / Q000187:drug effects; D013210:Staphylococcus / Q000187:drug effects
D000900:Anti-Bacterial Agents; D000892:Anti-Infective Agents, Urinary; D005839:Gentamicins; D011804:Quinolines; D002435:Cefamandole; D002939:Ciprofloxacin; D001390:Azlocillin; D002439:Cefotaxime; D003023:Cloxacillin; D008802:Mezlocillin; D002441:Cefsulodin